ID   KMS-5
AC   CVCL_A446
SY   KMS5; Kawasaki Medical School-5
DR   CGH-DB; 20-1
DR   CGH-DB; 9132-4
DR   Cosmic; 850215
DR   Wikidata; Q54900185
RX   DOI=10.1007/0-306-46877-8_4;
RX   PubMed=2519219;
RX   PubMed=2768132;
RX   PubMed=9290701;
RX   PubMed=9787181;
RX   PubMed=10936422;
RX   PubMed=15215163;
CC   Population: Japanese.
CC   Characteristics: Produces IgD lambda.
CC   Doubling time: 24 hours (PubMed=2519219).
CC   Omics: Array-based CGH.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   80Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-09-24; Version: 17
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).
//
RX   PubMed=2519219;
RA   Ohtsuki T., Yawata Y., Namba M.;
RT   "Establishment and characterization of five human myeloma cell
RT   lines.";
RL   Hum. Cell 2:297-303(1989).
//
RX   PubMed=2768132; DOI=10.1007/BF02623725;
RA   Namba M., Ohtsuki T., Mori M., Togawa A., Wada H., Sugihara T.,
RA   Yawata Y., Kimoto T.;
RT   "Establishment of five human myeloma cell lines.";
RL   In Vitro Cell. Dev. Biol. 25:723-729(1989).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2; PMCID=PMC1618545;
RA   Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S.,
RA   Taniwaki M., Inazawa J.;
RT   "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be
RT   associated with drug-resistance phenotype in multiple myeloma.";
RL   Am. J. Pathol. 165:71-81(2004).
//